All In Biotech

Drug Trial Radar · NCT06086613

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGA2115 in Adult Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Oct 3, 2023

Primary completion

Oct 17, 2024

Study completion Oct 17, 2024

Sponsor

Lead sponsor
Angitia Incorporated LimitedIndustry
Sponsor type
Industry
First posted
Oct 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • AGA2115Drug

    In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort). In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.

  • PlaceboDrug

    In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort). In Part B, participants will receive multiple doses of placebo administered as a SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Center

    Lake Forest, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.